Zentalis Pharmaceuticals (ZNTL) Short Interest Ratio & Short Volume → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free ZNTL Stock Alerts $11.06 +0.08 (+0.73%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Zentalis Pharmaceuticals Short Interest DataCurrent Short Volume16,640,000 sharesPrevious Short Volume15,530,000 sharesChange Vs. Previous Month+7.15%Dollar Volume Sold Short$220.81 millionShort Interest Ratio / Days to Cover20.4Last Record DateApril 15, 2024Outstanding Shares70,960,000 sharesPercentage of Shares Shorted23.45%Today's Trading Volume474,113 sharesAverage Trading Volume796,747 sharesToday's Volume Vs. Average60% Short Selling Zentalis Pharmaceuticals ? Sign up to receive the latest short interest report for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatZNTL Short Interest Over TimeZNTL Days to Cover Over TimeZNTL Percentage of Float Shorted Over Time Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. Zentalis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202416,640,000 shares $220.81 million +7.2%N/A20.4 $13.27 3/31/202415,530,000 shares $244.75 million -7.2%N/A19.1 $15.76 3/15/202416,740,000 shares $239.72 million +15.0%N/A20.3 $14.32 2/29/202414,560,000 shares $217.09 million +1.6%N/A16 $14.91 2/15/202414,330,000 shares $180.70 million +4.8%N/A17.6 $12.61 1/31/202413,670,000 shares $161.99 million +4.6%N/A13.7 $11.85 Get the Latest News and Ratings for ZNTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/202413,070,000 shares $186.38 million +2.5%N/A11.9 $14.26 12/31/202312,750,000 shares $193.16 million +10.0%N/A11.5 $15.15 12/15/202311,590,000 shares $170.03 million +4.5%N/A10.2 $14.67 11/30/202311,090,000 shares $124.76 million +4.8%N/A10.5 $11.25 11/15/202310,580,000 shares $124.00 million -5.0%N/A10.3 $11.72 10/31/202311,140,000 shares $182.25 million +4.1%N/A11.8 $16.36 10/15/202310,700,000 shares $202.66 million -5.1%N/A16.3 $18.94 9/30/202311,280,000 shares $226.28 million -0.1%N/A19.8 $20.06 9/15/202311,290,000 shares $264.30 million -5.9%N/A21.9 $23.41 8/31/202312,000,000 shares $318.72 million -3.2%N/A20.6 $26.56 8/15/202312,390,000 shares $342.46 million -7.0%N/A15.3 $27.64 7/31/202313,320,000 shares $355.78 million -2.9%N/A15.2 $26.71 7/15/202313,720,000 shares $385.81 million -5.4%N/A14.5 $28.12 6/30/202314,500,000 shares $409.05 million +9.3%N/A15 $28.21 6/15/202313,270,000 shares $368.24 million +7.9%N/A13.3 $27.75 5/31/202312,300,000 shares $320.29 million +15.8%N/A13.8 $26.04 5/15/202310,620,000 shares $297.57 million +8.0%N/A15.9 $28.02 4/30/20239,830,000 shares $216.55 million +9.1%N/A16.3 $22.03 4/15/20239,010,000 shares $164.34 million +1.2%N/A16.7 $18.24 3/31/20238,900,000 shares $153.08 million +10.2%N/A16.3 $17.20 3/15/20238,080,000 shares $147.62 million +0.9%N/A14.5 $18.27 2/28/20238,010,000 shares $151.63 million +1.3%N/A15.8 $18.93 2/15/20237,910,000 shares $161.13 million +5.3%N/A15.4 $20.37 1/31/20237,510,000 shares $177.24 million -4.6%N/A13.3 $23.60 1/15/20237,870,000 shares $196.28 million +23.6%N/A14.3 $24.94 12/30/20226,370,000 shares $128.29 million +14.6%N/A11.9 $20.14 12/15/20225,560,000 shares $107.75 million -8.1%N/A10.9 $19.38 11/30/20226,050,000 shares $133.83 million +4.7%N/A10.4 $22.12 11/15/20225,780,000 shares $132.59 million -3.0%N/A9.7 $22.94 10/31/20225,960,000 shares $149.54 million +1.4%N/A9.9 $25.09 10/15/20225,880,000 shares $135.65 million -2.0%N/A9.5 $23.07 9/30/20226,000,000 shares $129.96 million -1.2%N/A9.5 $21.66 9/15/20226,070,000 shares $154.06 million +0.3%N/A9.1 $25.38 8/31/20226,050,000 shares $162.20 million +4.0%N/A9.3 $26.81Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. ZNTL Short Interest - Frequently Asked Questions What is Zentalis Pharmaceuticals' current short interest? Short interest is the volume of Zentalis Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 16,640,000 shares of ZNTL short. Learn More on Zentalis Pharmaceuticals' current short interest. What is a good short interest ratio for Zentalis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZNTL shares currently have a short interest ratio of 20.0. Learn More on Zentalis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Zentalis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Zentalis Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Zentalis Pharmaceuticals' short interest increasing or decreasing? Zentalis Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 16,640,000 shares, an increase of 7.1% from the previous total of 15,530,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Zentalis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Zentalis Pharmaceuticals: Cassava Sciences, Inc. (29.69%), Immunome, Inc. (4.44%), OPKO Health, Inc. (23.81%), Tyra Biosciences, Inc. (13.78%), 89bio, Inc. (11.77%), Arcutis Biotherapeutics, Inc. (20.31%), Centessa Pharmaceuticals plc (2.14%), Tango Therapeutics, Inc. (19.37%), Innoviva, Inc. (18.46%), ARS Pharmaceuticals, Inc. (14.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Zentalis Pharmaceuticals stock? Short selling ZNTL is an investing strategy that aims to generate trading profit from Zentalis Pharmaceuticals as its price is falling. ZNTL shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Zentalis Pharmaceuticals? A short squeeze for Zentalis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ZNTL, which in turn drives the price of the stock up even further. How often is Zentalis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZNTL, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Cassava Sciences Short Interest Data Immunome Short Interest Data OPKO Health Short Interest Data Tyra Biosciences Short Interest Data 89bio Short Interest Data Arcutis Biotherapeutics Short Interest Data Centessa Pharmaceuticals Short Interest Data Tango Therapeutics Short Interest Data Innoviva Short Interest Data ARS Pharmaceuticals Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ZNTL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceBiden out June 13; Kamala won’t replace him?Paradigm Press